Skip to content
To the full analysis

Dyne Therapeutics stock: balance sheet and debt

DYN
$17.01Closing price of 12 Nov 2026MEQIRI Score 34 out of 100

Dyne Therapeutics has a debt to equity ratio of 0.02.

Daily figure as of 13 Nov 2026

Debt / Equity
0.02
Interest coverage
−50x
Current ratio
20
Cash & equivalents
$1.11B
Total assets
$1.19B
Equity ratio
81.9%
Goodwill
not reported separately
Net debt
−$1.09B
More cash than debt

Total assets and equity ratio

How large the balance sheet of Dyne Therapeutics, Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2007$13.22B$935M$438M34.1%−$330M
2008$14.21B$870M$433M31.8%−$652M
2009$10.95B$380Mnot split out26.5%$1.07B
2010$10.01B$141Mnot split out27.4%$4.18B
2011$4.13Bnot reported separatelynot reported separately26.9%$123M
2012$4.54B$271Mnot split out55.2%$1.05B
2013$5.29B$108Mnot split out41.8%$1.12B
2014$11.23B$27Mnot split out26.9%$5.16B
2015$11.54B$899M$797M25.3%$6.68B
2016$13.05B$837M$799M15.6%$7.07B
2017$11.77B$797M$772M16.1%$8.04B
2018$8.27Mnot reported separatelynot reported separately−59.0%−$4.75M
2019$16.44Mnot reported separatelynot reported separately85.4%−$14.63M
2020$353.33Mnot reported separatelynot reported separately96.9%−$345.31M
2021$425.66Mnot reported separatelynot reported separately86.5%−$343.94M
2022$306.33Mnot reported separatelynot reported separately82.4%−$225.53M
2023$165.08Mnot reported separatelynot reported separately55.3%−$95.69M
2024$691.23Mnot reported separatelynot reported separately91.1%−$618.28M
2025$1.19Bnot reported separatelynot reported separately81.9%−$1.09B

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2007$432M$4.51B$102M0.02
2008$780M$4.52B$128M0.03
2009$549M$2.9B$1.61B0.56
2010$397M$2.75B$4.57B1.67
2011$465M$1.11B$588M0.53
2012$361M$2.5B$1.42B0.57
2013$868M$2.21B$1.99B0.9
2014$1.95B$3.02B$7.11B2.35
2015$605M$2.92B$7.29B2.5
2016$1.91B$2.04B$8.98B4.4
2017$397M$1.9B$8.43B4.44
2018$8.12M−$4.88M$3.38M−0.69
2019$14.63M$14.04M$00
2020$345.31M$342.37M$00
2021$376.57M$368.2M$32.64M0.09
2022$256.01M$252.36M$30.48M0.12
2023$123.1M$91.29M$27.42M0.3
2024$642.27M$629.84M$23.99M0.04
2025$1.11B$972.13M$20.28M0.02

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2021)
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy